WuXi AppTec (stock code: 603259.SH/2359. HK) provides integrated, end-to-end new drug research and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers research and development thresholds, helps customers improve research and development efficiency, and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and other fields. In 2023, WuXi AppTec was rated as ESG (Environmental, Social, and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D innovation projects from over 6000 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients worldwide, and realizing the vision of "making the world without difficult drugs and difficult diseases" as soon as possible.
Odor components | Odor inlet indicators | Odor discharge indicators | Exhaust pipe height |
H2S | ≤100mg/m3 | ≤0.6kg/h | 15m |
NH3 | ≤40mg/m3 | ≤0.6kg/h | |
C2H6S | ≤50mg/m3 | ≤0.6kg/h | |
Odour | ≤3000 | ≤800 |